• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Respiratory/Inflammation
  • A comparative, placebo-controlled, double blind, double dummy, cross-over, single centre, phase IIIb study between formoterol alone (Oxis Turbuhaler 4.5 µg) and the fixed combination of formoterol and budesonide (Symbicort Turbuhaler 160/4.5 µg) on airway responsiveness and airway inflammation induced by repeated low-dose allergen challenge in allergic patients with mild asthma.

Disease
asthma
Drug Name
Symbicort
Generic Name
budesonide/formoterol
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
III
Start Date
Oct 22, 2004
Study Name
D5890L00007
Study Id
D5890L00007
Recruiting Status
Closed
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013